生殖医学杂志

参考文献

[1] Koltai T,Fliegel L. The relationship between Trop-2,chemotherapeutic drugs,and chemoresistance[J].Int J Mol Sci,2023,25:87.

[2] Qiu S,Zhang J,Wang Z,et al.Targeting Trop-2in cancer:recent research progress and clinical application[J].Biochim Biophys Acta Rev Cancer,2023,1878:188902.

[3] Tymon-Rosario J, Gorman M, Richardson DL,et al.Advances in antibody-drug conjugates for gynecologic malignancies[J].Curr Opin Obstet Gynecol,2023,35:6-14.

[4] Wen Y,Ouyang D,Zou Q,et al.A literature review of the promising future of TROP2:apotential drug therapy target[J].Ann Transl Med,2022,10:1403.

[5] Hou J,Lv A,Deng Q,et al. TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2/STAT3signaling pathway[J].Oncol Rep,2019,41:753-764.

[6] Tang G,Tang Q,Jia L,et al.TROP2increases growth and metastasis of human oral squamous cell carcinoma through activation of the PI3K/Akt signaling pathway[J].Int J Mol Med,2019,44:2161-2170.

[7] Stoyanova T,Goldstein AS,Cai H,et al. Regulated proteolysis of Trop2drives epithelial hyperplasia and stem cell self-renewal viaβ-catenin signaling[J].Genes Dev,2012,26:2271-2285.

[8] Wu B,Yu C,Zhou B,et al. Overexpression of TROP2promotes proliferation and invasion of ovarian cancer cells[J].Exp Ther Med,2017,14:1947-1952.

[9] Sun X,Xing G,Zhang C,et al.Knockdown of Trop2inhibits proliferation and migration and induces apoptosis of endometrial cancer cells via AKT/β-catenin pathway[J].Cell Biochem Funct,2020,38:141-148.

[10] Liu T,Liu Y,Bao X,et al. Overexpression of TROP2predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway[J/OL].PLoS One,2013,8:e75864.

[11] Salerno EP,Bedognetti D, Mauldin IS,et al. Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk[J].Oncoimmunology,2016,5:e1240857.

[12] Bessede A,Peyraud F,Besse B,et al.TROP2is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-Small cell lung cancer[J].Clin Cancer Res,2024,30:779-785.

[13] Morgenstern-Kaplan D,Kareff SA, Trabolsi A,et al.Genomic,immunologic,and prognostic associations of TROP2(TACSTD2)expression in solid tumors[J].Oncologist,2024,29:e1480-e1491.

[14] Wang X,Long M,Dong K,et al.Chemotherapy agentsinduced immunoresistance in lung cancer cells could be reversed by trop-2inhibition in vitro and in vivo by interaction with MAPK signaling pathway[J].Cancer Biol Ther,2013,14:1123-1132.

[15] Chiba Y,Kojima Y,Yazaki S,et al.Trop-2expression and the tumor immune microenvironment in cervical cancer[J].Gynecol Oncol,2024,187:51-57.

[16] Lai J,Deng S,Cao J,et al.Identification of biomarker associated with Trop2 in breast cancer:implication for targeted therapy[J].Discov Oncol,2024,15:413.

[17] Anastasio MK,Shuey S,Davidson BA. Antibody-drug conjugates in gynecologic cancers[J].Curr Treat Options Oncol,2024,25:1-19.

[18]乔山峰，张春艳，丁小丽，等．高级别浆液性卵巢癌患者血清CD26、CD109与临床病理特征和预后的关系研究[J]．生殖医学杂志，2024,33:907-912.

[19] Han X,Gao Y,Jiang M,et al. Single-cell and spatial transcriptome sequencing uncover a platinum-resistant cluster overexpressed TACSTD2in high-grade serous ovarian cancer[J].J Cancer,2024,15:3427-3440.

[20]冯倩倩，卢丹．TROP2在宫颈病变中的表达及临床研究[J]．实用妇科内分泌电子杂志，2020,7:53-57.

[21] Bignotti E,Zanotti L,Calza S,et al. Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma[J].BMC Clin Pathol,2012,12:22.

[22] FucàG,Sabatucci I,Paderno M,et al.The clinical landscape of antibody-drug conjugates in endometrial cancer[J].Int J Gynecol Cancer,2024,34:1795-1804.

[23]龙腾飞，程玲慧，王彦，等．人滋养细胞表面抗原（Trop-2）在病变子宫内膜中表达的研究[J]．现代生物医学进展，2020,20:4793-4796.

[24] Bignotti E,Todeschini P,Calza S,et al.Trop-2overexpression as an independent marker for poor overall survival in ovarian carcinoma patients[J].Eur J Cancer,2010,46:944-953.

[25]杨旭峰，雷龙春，成争艳．宫颈鳞癌组织TROP2蛋白的表达特点及其与预后的相关性[J]．临床与病理杂志，2018,38:2371-2377.

[26] Pavone G,Motta L,Martorana F,et al.A new kid on the block:sacituzumab govitecan for the treatment of breast cancer and other solid tumors[J].Molecules,2021,26:7294.

[27] Perrone E,Lopez S,Zeybek B,et al.Preclinical activity of sacituzumab govitecan,an antibody-drug conjugate targeting trophoblast cell-surface antigen 2(Trop-2)linked to the active metabolite of irinotecan(SN-38),in ovarian cancer[J].Front Oncol,2020,10:118.

[28] Zeybek B,Manzano A,Bianchi A,et al.Cervical carcinomas that overexpress human trophoblast cell-surface marker(Trop-2)are highly sensitive to the antibody-drug conjugate sacituzumab govitecan[J].Sci Rep,2020,10:973.

[29] Perrone E,Manara P,Lopez S,et al.Sacituzumab govitecan,an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo[J].Mol Oncol,2020,14:645-656.

[30] Santin AD,Corr BR,Spira A,et al.Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors(TROPiCS-03):analysis in patients with advanced endometrial cancer[J].J Clin Oncol,2024,42:3421-3429.

[31] An J,Li G,Zhang Y,et al.Sacituzumab govitecan for Chinese patients with recurrent/metastatic cervical cancer:interim analysis of the phase II basket study EVER-132-003[J].Gynecol Oncol,2024,190:S22.

[32] Okajima D,Yasuda S,Maejima T,et al. Datopotamab deruxtecan,a novel TROP2-directed antibody-drug conjugate,demonstrates potent antitumor activity by efficient drug delivery to tumor cells[J]. Mol Cancer Ther,2021,20:2329-2340.

[33] McNamara B,Greenman M,Bellone S,et al. Preclinical activity of datopotamab deruxtecan,a novel TROP2directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2(TROP2)in ovarian carcinoma[J].Gynecol Oncol,2024,189:16-23.

[34] Oaknin A,Ang JE,Rha SY,et al.714MO Datopotamab deruxtecan(Dato-DXd)in patients with endometrial(EC)or ovarian cancer(OC):Results from the phase II TROPIONPanTumor03study[J].Ann Oncol,2024,35:S547-S548.

[35] Wang D,Wang K,An R,et al.715MO Safety and efficacy of sacituzumab tirumotecan(sac-TMT)in patients(pts)with previously treated advanced endometrial carcinoma(EC)and ovarian cancer(OC)from a phaseⅡstudy[J].Ann Oncol,2024,35:S548.

[36] Wang J,An R,Huang Y,et al.716MO Efficacy and safety of sacituzumab tirumotecan(sac-TMT)plus pembrolizumab in patients with recurrent or metastatic cervical cancer[J].Ann Oncol,2024,35:S548-S549.

[37] Coates JT,Sun S,Leshchiner I,et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triplenegative breast cancer[J]. Cancer Discov,2021,11:2436-2445.

[38] Jo A,Shoji T,Otsuka H,et al.Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitors[J].Int J Clin Oncol,2025,30:229-240.

[39] Shang X,Su H,Chen X,et al.Low-dose lenvatinib and antiprogrammed cell death protein-1 combination therapy in patients with heavily pre-treated recurrent ovarian and endometrial cancer:apilot study[J].Int J Gynecol Cancer,2024,34:1203-1210.

[40] Chung YM,Khan PP,Wang H,et al.Sensitizing tumors to anti-PD-1therapy by promoting NK and CD8+T cells via pharmacological activation of FOXO3[J].J Immunother Cancer,2021,9:e002772.

[41] Cardillo TM,Sharkey RM,Rossi DL,et al. Synthetic lethality exploitation by an anti-Trop-2-SN-38antibody-drug conjugate,IMMU-132,plus PARP inhibitors in BRCA1/2-wild-type triple-negative breast cancer[J].Clin Cancer Res,2017,23:3405-3415.